Brainsway Ltd. (TASE:BRIN) today announced good interim results of the safety and effectiveness trial of its Deep Transcanial Magnetic Stimulation (Deep TMS) device for the treatment of Alzheimer's disease. The trial on the first ten patients is underway at the Sourasky Medical Center Tel Aviv (Ichilov Hospital).
All the ten patients undergoing the trial were in good shape, and suffered no side effects. The hospital ethics committee (Helsinki committee) was notified of several incidents, which the chief researcher, Dr. Eliahu Simon, believes were unrelated to the treatment.
The trial used the Mini Mental State Examination (MMSE) and the Alzheimer's Disease Assessment Scale - cognitive (ADAS-cog) test to assess Deep TMS's effectiveness. Both tests are the main effectiveness tests in the literature. Six of the ten patients completed the full study. One of the patients in the control was removed from the study.
The six patients who completed the MMSE test showed, on average, improvement compared with the patients who took a placebo. The six patients who completed the ADAS-cog test showed, on average, the most significant improvement compared with the patients who took a placebo.
Dr. Simon's interim report says that these results indicate significantly improved cognitive function by the patients who underwent Deep TMS treatment.
Brainsway's share rose 1.6% today to NIS 11.97, giving a market cap of NIS 512 million.
Published by Globes [online], Israel business news - www.globes-online.com - on January 24, 2010
© Copyright of Globes Publisher Itonut (1983) Ltd. 2010